Related Experiment Video
Updated: May 10, 2026
06:43
Quantitative Analysis and Characterization of Atherosclerotic Lesions in the Murine Aortic Sinus
Published on: December 7, 2013
Atherosclerosis in systemic lupus erythematosus.
George Stojan1, Michelle Petri
1Division of Rheumatology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD.
Journal of Cardiovascular Pharmacology
|June 25, 2013
Summary
Systemic lupus erythematosus (SLE) patients face accelerated atherosclerosis and mortality. While traditional risk factors are important, SLE-specific factors and certain treatments like hydroxychloroquine are key for managing cardiovascular risk in these patients.
Area of Science:
- Cardiovascular Medicine
- Rheumatology
- Immunology
Background:
- Accelerated atherosclerosis is a primary cause of mortality in Systemic Lupus Erythematosus (SLE) patients.
- Traditional cardiovascular risk factors inadequately explain the elevated risk in SLE.
- SLE-specific factors, including disease activity, duration, corticosteroid use, and antiphospholipid antibodies, significantly contribute to cardiovascular risk.
Purpose of the Study:
- To review the cardiovascular risk factors and management strategies in patients with Systemic Lupus Erythematosus.
- To evaluate the efficacy of various therapeutic interventions on cardiovascular outcomes in SLE.
Main Methods:
- Literature review of studies on cardiovascular disease in SLE.
- Analysis of traditional and SLE-specific risk factors for atherosclerosis.
- Evaluation of pharmacological interventions, including statins, hydroxychloroquine, mycophenolate mofetil, vitamin D, and homocysteine treatments.
Main Results:
- Statins show limited efficacy in preventing cardiovascular outcomes in SLE populations.
- Hydroxychloroquine demonstrates cardioprotective effects.
- Mycophenolate mofetil may reduce cardiovascular events, supported by preclinical and transplant data.
- The benefits of vitamin D supplementation and hyperhomocysteinemia treatment remain debated but are considered optional therapies due to safety profiles.
Conclusions:
- Systemic Lupus Erythematosus is considered a coronary heart disease equivalent, necessitating aggressive management of all risk factors.
- Hydroxychloroquine and potentially mycophenolate mofetil are beneficial for cardiovascular health in SLE patients.
- Further research is needed to clarify the role of vitamin D and homocysteine management in SLE cardiovascular disease prevention.
Related Concept Videos
01:30Atherosclerosis I: Introduction
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
01:27Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:23Atherosclerosis IV: Nursing Management
Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...
01:30Peripheral Artery Disease I: Introduction
Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
01:23Rheumatic Heart Disease I: Introduction
Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...